Global Genetically Engineered Animal Models & Services Market Size is valued at USD 1.4 Bn in 2024 and is predicted to reach USD 3.8 Bn by the year 2034 at a 10.3% CAGR during the forecast period for 2025-2034.
Genetically Engineered Animal Models & Services entail the breeding of animals, primarily mice or rats, with altered genes to investigate human diseases, evaluate pharmaceuticals, and comprehend gene functions. Services encompass model construction, colony maintenance, genotyping, and preclinical testing. These models are crucial for pharmacological discovery, gene therapy assessment, and disease investigation. In biomedical research, these models are frequently employed to understand genetics and physiology better, investigate the underlying causes of diseases, and create and test possible remedies.
The growing need for cutting-edge research techniques and the rising incidence of chronic illnesses are the main factors propelling the market for genetically engineered animal models and services. Non-communicable diseases account for 71% of deaths worldwide, according to the World Health Organization (WHO), which has led to a surge in research efforts to determine the genetic foundation of these illnesses. Furthermore, researchers are being pushed to use genetically engineered animals in order to more accurately evaluate the safety and efficacy of drugs due to the pharmaceutical industry's demand for rapid drug development processes. These models allow scientists to more closely simulate human illnesses, which facilitates the creation of tailored treatments and personalized medicine solutions.
However, regulatory barriers can prolong and complicate research timeframes by slowing down the development and approval processes for genetically modified animals. Companies aiming to enter or grow within this sector may encounter obstacles because of the strict rules enforced by agencies such as the U.S. Food and Drug Administration (FDA). Whereas partnerships between commercial biotech companies and university institutions might help create novel models that propel market expansion. According to the National Science Foundation (NSF), the increase in financing for biotechnology research also indicates a favorable climate for developments in genetically engineered animal models & services.
Competitive Landscape
Some Major Key Players In The Genetically Engineered Animal Models & Services Market:
- Charles River Laboratories
- Envigo
- GenOway
- Celerion
- Crown Bioscience
- Horizon Discovery
- Crown Bioscience
- Jackson Laboratory
- Taconic Biosciences
- In Vivo Therapeutics
- BioIVT
- Celerion
- Other Market Players
Market Segmentation:
The Genetically Engineered Animal Models & Services market is segmented based on Type of Services, Application, and End-user. The market is segmented by type of services into Custom Model Development, Consultation Services, Model Validation, Breeding Services, and Maintenance Services. By application, it includes Oncology, Immunology, Metabolic Disorders, Cardiovascular Diseases, and Neurological Disorders. Based on end-user, the market comprises Biotechnology Companies, Pharmaceutical Companies, Contract Research Organizations, Academic and Research Institutes, and Government Organizations.
Based On The Type Of Services, The Adult Genetically Engineered Animal Models & Services Segment Is Accounted As A Major Contributor To The Genetically Engineered Animal Models & Services Market
The oncology category is expected to hold a major global market share in 2024, fueled by the growing need for better predictive preclinical models and the rising death rate from cancer. Oncology researchers frequently use genetically engineered animal models & services, especially mouse models, to mimic the pathophysiology of human cancer. This allows them to examine tumor growth, metastasis, and response to treatment in a controlled setting. Advanced animal models that can replicate particular genetic abnormalities seen in human tumors are becoming increasingly necessary due to the rise in targeted therapy development, immuno-oncology medications, and personalized medicine.
Biotechnology Companies Segment To Witness Growth At A Rapid Rate
The market for genetically engineered animal models and services is expanding significantly in the Biotechnology Companies sector due to the growing complexity of drug development pipelines and the growing need for sophisticated preclinical research models. These businesses are using genetically engineered animal models & services to evaluate drug efficacy and safety before clinical trials, discover new therapeutic targets, and get a deeper understanding of disease causes. The quick uptake of CRISPR and other gene-editing technologies has further enabled biotechnology companies to produce accurate, personalized animal models, spurring innovation efficiently.
In The Region, The North American Genetically Engineered Animal Models & Services Market Holds A Significant Revenue Share
The North American Genetically Engineered Animal Models & Services market is expected to register the highest market share in revenue in the near future. The enormous investments in research and development, established research infrastructure, and the presence of numerous pharmaceutical and biotechnology companies are the reasons for the region's leadership. North America's market is growing mostly due to the United States, as the National Institutes of Health (NIH) is the world's largest supporter of biomedical research.
In addition, Asia Pacific is projected to grow rapidly in the global Genetically Engineered Animal Models & Services market. The need for genetically engineered animal models & services is being driven by the significant investments made in biotechnology and life sciences research by nations like China, Japan, and India.
Genetically Engineered Animal Models & Services Market Report Scope :
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 1.4 Bn |
|
Revenue Forecast In 2034 |
USD 3.8 Bn |
|
Growth Rate CAGR |
CAGR of 10.3% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ BN and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type of Services, Application, and End-user |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Charles River Laboratories, Envigo, GenOway, Celerion, Crown Bioscience, Horizon Discovery, Crown Bioscience, Jackson Laboratory, Taconic Biosciences, In Vivo Therapeutics, BioIVT, and Celerion. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
